News and Announcements
Kazia, a company developing innovative high-impact drugs for cancer, presents to AusBiotech Invest
- Published November 04, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Kazia, developing innovative, high-impact drugs for cancer has presented to AusBiotech Invest.
Investment Rationale:
- Our lead program, GDC-0084, was designed by Genentech, the world’s most successful cancer drug developer, and has completed a successful phase 1 human trial, showing it to be generally safe and providing signals of efficacy
- GDC-0084 is a PI3K inhibitor, a well-validated and well-understood class of cancer therapies with four FDA-approved products; unique differentiating feature of GDC-0084 is the ability to cross the blood-brain barrier
- Five clinical trials of GDC-0084 are currently underway at leading US hospitals, of which four are primarily funded by external parties, covering a broad range of primary and secondary brain cancers to provide multiple shots on goal
- Company is well-financed, following a recent institutional placement, with new interim efficacy data from lead program expected in November 2019; pivotal study for registration expected to commence in 2020
Read Full Article
For more information on Kazia register your interest below.
Company Updates
Forget Startups: Why Magnetic Alliance is Betting on “Boring” Mid-Market Turnarounds
While Australia’s venture capital scene spent years chasing unprofitable tech startups and speculative high-growth plays, Mark Lim was quietly taking a radically different path. The Managing Partner of Magnetic Alliance Capital sees the nation’s richest investment opportunities hiding in plain sight: inside thousands of unglamorous, profitable, but operationally sluggish mid-market businesses. Speaking on Wholesale Investor’s […]
The asset class where the market has no vote
Litigation funding returns are decided in a courtroom, not a cycle. Knightsbridge’s Head of Capital is careful to call that a different risk rather than a lower one, and his answer to it is spread, not concentration. Most alternative assets still answer to something. Property answers to rates. Private credit answers to defaults. Even the […]
The listing fee vendors pay whether the house sells or not
Australia’s property portals collect more than $2 billion a year while national listings sit flat. An Australian-built AI platform is targeting the economics, not just the interface. An Australian vendor listing a home pays a vendor-paid advertising fee on top of agency commission. Rama Dwarapudi, Founder and Chief Executive Officer of RealSearch, puts a typical […]
Backed By Leading Investment Groups and Family Offices
